Figure 5.

NGAL confers resistance to erlotinib-induced tumor growth inhibition in SCID mice. A: H3255 Vector control and NGAL overexpressing cells were injected subcutaneously into SCID mice (5 mice per group). Ten days post-tumor inoculation, mice were treated with erlotinib at 0.5 mg/kg or 1 mg/kg daily, and tumor volumes were measured. Tumors derived from NGAL overexpressing cells were significantly more resistant to erlotinib treatment than vector control-derived tumors (**p < 0.001). Error bars represent the standard deviation. B: After mice were sacrificed, the diluent-treated tumors were homogenized, and tumor lysates were analyzed for Erk and Akt pathway activation and NGAL and Bim protein by Western blot.